Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 16 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Social Capital Suvretta Holdings Corp. II | 6,220,000 | reported | 16 Aug 2021 | tx 1−75,000 |
| PROKIDNEY CORP. | 3,193,175 | reported | 31 Mar 2023 | tx 6+868,375−3,087,000 |
| Benitec Biopharma Inc. | 1,848,156 | reported | 29 Dec 2025 | tx 12+1,091,743 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 23 Dec 2025 | PURCHASE | Benitec Biopharma Inc. | 7,400 | 12.85 USD | |
| 23 Dec 2025 | PURCHASE | Benitec Biopharma Inc. | 42,600 | 12.85 USD | |
| 26 Dec 2025 | PURCHASE | Benitec Biopharma Inc. | 14,320 | 13.10 USD | |
| 26 Dec 2025 | PURCHASE | Benitec Biopharma Inc. | 2,516 | 13.10 USD | |
| 29 Dec 2025 | PURCHASE | Benitec Biopharma Inc. | 65,800 | 13.44 USD | |
| 29 Dec 2025 | PURCHASE | Benitec Biopharma Inc. | 11,587 | 13.44 USD | |
| 26 Mar 2025 | PURCHASE | Benitec Biopharma Inc. | 793,800 | 13.00 USD | |
| 26 Mar 2025 | PURCHASE | Benitec Biopharma Inc. | 106,200 | 13.00 USD | |
| 24 Dec 2024 | PURCHASE | Benitec Biopharma Inc. | 2,288 | 11.25 USD | |
| 24 Dec 2024 | PURCHASE | Benitec Biopharma Inc. | 17,730 | 11.25 USD | |
| 23 Dec 2024 | PURCHASE | Benitec Biopharma Inc. | 24,360 | 10.98 USD | first after silence |
| 23 Dec 2024 | PURCHASE | Benitec Biopharma Inc. | 3,142 | 10.98 USD | |
| 31 Mar 2023 | OTHER | PROKIDNEY CORP. | 857,500 | 0.00 USD | |
| 31 Mar 2023 | OTHER | PROKIDNEY CORP. | 3,087,000 | 0.00 USD | |
| 06 Sept 2022 | PURCHASE | PROKIDNEY CORP. | 7,007 | 6.99 USD | |
| 30 Aug 2022 | PURCHASE | PROKIDNEY CORP. | 706 | 7.49 USD | |
| 31 Aug 2022 | PURCHASE | PROKIDNEY CORP. | 1,062 | 8.93 USD | |
| 31 Aug 2022 | PURCHASE | PROKIDNEY CORP. | 2,100 | 8.94 USD | |
| 16 Aug 2021 | OTHER | Social Capital Suvretta Holdings Corp. II | 75,000 | 0.00 USD | deriv |
1 purchase reported after at least 12 months of silence — most recent on 23 Dec 2024.